Zepto vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mumbai India quick commerce (YC W21) at 29% market share with 1,000+ dark stores in 35 cities; $2.3B+ total ($450M at $7B Oct 2025) for 2026 IPO competing with Blinkit for Indian 10-minute grocery delivery.
About
Zepto is a Mumbai, India-based quick commerce platform — backed by Y Combinator (W21) with $2.3+ billion in total funding including a $450 million round in October 2025 at a $7 billion valuation from General Catalyst, CalPERS, and other investors — providing Indian consumers in 35 cities with grocery and essential delivery in 10 minutes through a network of 1,000+ dark stores (micro-fulfillment centers) processing 1.1+ million daily orders. Holding approximately 29% market share in India's quick commerce sector (behind Blinkit's 46% and ahead of Swiggy Instamart's 25%) in a market projected to reach $9.95 billion by 2029, with 75% of stores EBITDA positive and an IPO planned for 2026. Founded in July 2021 by 19-year-old Stanford dropouts Aadit Palicha (CEO) and Kaivalya Vohra.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.